Compounds > alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol
Page last updated: 2024-09-02

alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and mr 2266

alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol has been researched along with mr 2266 in 1 studies

Compound Research Comparison

Studies
(alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol)		Trials
(alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol)		Recent Studies (post-2010)
(alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol)		Studies
(mr 2266)		Trials
(mr 2266)		Recent Studies (post-2010) (mr 2266)
901217600

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Iwamoto, ET1

Other Studies

1 other study(ies) available for alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and mr 2266

ArticleYear
Evidence for a model of activation of central sigma systems.
    Life sciences, 1989, Volume: 44, Issue:21

    Topics: Animals; Benzazepines; Benzomorphans; Butaclamol; Carbazoles; Dopamine Antagonists; Haloperidol; Kinetics; Male; Models, Biological; Motor Activity; Naltrexone; Narcotic Antagonists; Phenazocine; Pyrimidines; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, sigma; Sulpiride

1989